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Background/aim: In this retrospective study, the efficacy of ertapenem and piperacillin tazobactam was compared in the treatment of
complicated urinary tract infections (cUTIs). Treatment responses were also evaluated for both antibiotics.
Materials and methods: A total of 230 patients were enrolled in the study. Of these, 170 received ertapenem and 60 received piperacillintazobactam.
Results: In both groups, urine cultures after 48 h were negative for the initial uropathogen. The frequency of superinfection was 29.4% in
the ertapenem group and 8.3% in the piperacillin-tazobactam group over the duration of treatment (P < 0.05). Urinary catheterization
increased the superinfection risk 2.88-fold in the ertapenem group and diabetes mellitus increased the risk 8.50-fold in the piperacillintazobactam group (CI: 1.44–5.76 and 1.16–62.09, respectively, P < 0.05). The main pathogen isolated from superinfection in the
ertapenem group after 48 h was Enterococcus spp. (71.4%).
Conclusion: Both ertapenem and piperacillin-tazobactam were effective in the treatment of cUTIs caused by ESBL-producing
microorganisms. A high frequency of superinfection in the ertapenem group was the result of Enterococcus and Pseudomonas spp.,
against which ertapenem is not active. In the presence of urinary catheterization, diabetes mellitus, and urological intervention, patients
should be closely monitored for the development of a superinfection, especially patients receiving ertapenem.
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1. Introduction
Complicated urinary tract infections (cUTIs) are a major
cause of hospital admissions and are the most frequent
cause of nosocomial infections. They are also associated
with significant morbidity and increased healthcare
costs (1). Resistance to first-line antimicrobials, such as
fluoroquinolones, cotrimoxazole, and oral cephalosporins,
among urinary Escherichia coli and Klebsiella isolates
limits the therapeutic options in some geographic
regions, including Turkey. Carbapenems and betalactam/
betalactamase inhibitor combinations remain the drugs
of choice for the treatment of severe infections due to
extended spectrum beta-lactamase (ESBL)producing
Enterobacteriaceae (1,2). Few studies have evaluated the
comparative activity of carbapenems and beta-lactam/
beta-lactamase inhibitor combinations.
In this study, we aimed to compare the activity of
ertapenem and piperacillintazobactam for the treatment
of cUTIs due to ESBL-producing E. coli and Klebsiella spp.
* Correspondence: mrkrshn@hotmail.com
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We also analyzed the risk factors for the development of a
superinfection during treatment.
2. Materials and methods
This study was conducted retrospectively with patients
who had been hospitalized in various clinics of Gazi
University Hospital from January 2008 to April 2012.
During this period, patients were included if they were
diagnosed as having a cUTI due to ESBLproducing E. coli
and Klebsiella spp. The patients were separated into two
groups according to whether they received ertapenem or
piperacillin-tazobactam treatment.
The patients’ data were obtained from their files
and laboratory records. Data from patients who grew
≥105 colony forming units (cfu) of ESBL-positive E. coli and
Klebsiella spp. in baseline urine cultures and were treated
for cUTIs were analyzed retrospectively for cUTI risk
factors. The presence of functional and anatomical defects,
an indwelling catheter, immunosuppression, recurrent
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urinary tract infections, prior antibiotic use, diabetes
mellitus, urological interventions, and nephrolithiasis were
accepted as markers of a cUTI (3). Patients less than 18
years of age and patients who were treated with antibiotics
other than ertapenem and piperacillin-tazobactam were
excluded from the study.
The microbiological response of each patient was
evaluated after 48 h of treatment, and then once again
(median: 5th day) during the treatment. Microbiological
responses were defined as follows: eradication
(uropathogen ≥105 cfu/mL at entry reduced to <104 cfu/
mL); persistence (urine culture grew ≥104 cfu/mL of an
initial uropathogen); and superinfection (urine culture
during therapy grew ≥105 cfu/mL of a pathogen other
than the initial pathogen) (4). Treatment responses
(eradication, persistence, and superinfection), outcomes,
and the risk factors for cUTI in both the ertapenem and
piperacillin-tazobactam groups were compared using
SPSS 15.0 (SPSS Inc., Chicago, IL, USA). The risk factors
affecting the development of a superinfection were also
analyzed. Continuous variables are presented as mean ±
standard deviation and median (minimum, maximum),
while categorical variables are given as a number and

percentage. Continuous variables were compared with the
Mann–Whitney U test and categorical variables with the
chisquare test. P < 0.05 was considered significant.
Logistic regression (LR) models were built to determine
the risk factors of a superinfection (last step was presented,
method: backward LR, entry: 0.05, removal: 0.10). The
LR model of superinfections under treatment included
urinary catheterizations, nephrolithiasis, diabetes mellitus,
urological interventions, immunosuppression, recurrent
urinary tract infections, and antibiotic treatment within
the last 3 months. The LR model for the risk factors of
an enterococcal superinfection in the ertapenem group
included urinary catheterizations, nephrolithiasis, diabetes
mellitus, urological interventions, urinary malignancies,
recurrent urinary tract infections, and antibiotic treatment
within the last 3 months.
3. Results
A total of 230 patients were enrolled in this study. Of these,
170 received ertapenem and 60 received piperacillintazobactam. The distribution of the patients’ descriptive
characteristics is presented in Table 1. The frequency of
malignancy, history of recurrent urinary tract infections,

Table 1. Distribution of patients’ descriptive characteristics.
Characteristics

Ertapenem
(n = 170) (n, %)

Piperacillin-tazobactam
(n = 60) (n, %)

P

Age, mean ± SD, median (min, max)

59.54 ± 16.80,
61.0 (18, 95)

57.63 ± 18.62,
60.50 (18, 90)

0.95

Female

79 (46.47)

28 (46.66)

0.79

Male

91 (53.53)

32 (53.34)

Duration of treatment, mean ± SD, median (min, max)

10.89 ± 5.22,
10 (2, 34)

10.25 ± 4.77,
10 (2, 32)

0.05

Diabetes mellitus

44 (25.9)

12 (20.0)

0.46

Malignancy

38 (22.4)

5 (8.3)

0.02

Urinary tract malignancy

26 (15.3)

12 (20.0)

0.52

Immunosuppression

25 (14.7)

15 (25.0)

0.10

Recurrent urinary tract infection

47 (27.6)

32 (53.3)

0.001

Nephrolithiasis

26 (15.3)

15 (25.0)

0.13

Neurogenic bladder

20 (11.8)

9 (15.0)

0.67

Urinary incontinence

7 (4.1)

2 (3.3)

1.00

Urethral stricture

15 (8.8)

4 (6.7)

0.78

Hyperplasia of prostate

36 (21.2)

8 (13.3)

0.25

Urinary catheterization

72 (42.6)

37 (61.7)

0.17

Antibiotic treatment within last 3 months

53 (31.2)

32 (53.3)

0.02

Urological intervention

60 (35.3)

29 (48.3)

0.07

Sex
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and the presence of antibiotic treatment within the last 3
months were significantly different between the ertapenem
and piperacillintazobactam treatment groups (P < 0.05).
In both groups, urine cultures after 48 h were negative
for the initial uropathogens. However, the frequency
of superinfections was 29.4% in the ertapenem group
and 8.3% in the piperacillin-tazobactam group over the
duration of the treatment. This difference between groups
was statistically significant (P < 0.05). The frequency of
superinfection in both groups is shown in Table 2.
Thirty-five patients developed a superinfection in the
ertapenem group; at the 48-h urine culture, the isolated
microorganisms included Enterococcus spp. (n = 25),
Pseudomonas spp. (n = 4), Candida spp. (n = 4), and S.
maltophilia (n = 2). In the piperacillin-tazobactam group,
only five patients had superinfections and all of these were
due to Candida spp.
Urine cultures after the 48th hour of treatment were
positive in 22 patients in the ertapenem group and in
one patient in the piperacillin-tazobactam group. The
isolated microorganisms included Enterococcus spp. (n
= 13), Candida spp. (n = 6), S. maltophilia (n = 2), and
Pseudomonas sp. (n = 1) in the ertapenem group and
Candida sp. (n = 1) in the piperacillin-tazobactam group.
Of seven patients in the ertapenem group and one patient
in the piperacillin-tazobactam group, urine cultures grew
different microorganism at the 48th and after the 48th
hour.

Superinfection risk factors for the total duration of
treatment were analyzed using the LR model. Urinary
catheterization increased the superinfection risk 2.88fold (CI: 1.44–5.76) in the ertapenem group (P < 0.05),
and diabetes mellitus increased the risk 8.50-fold (CI:
1.16–62.09) fold in the piperacillin-tazobactam group (P
< 0.05).
The main pathogen isolated from superinfections in the
ertapenem group after 48 h was Enterococcus spp. (71.4%).
When the risk factors for an enterococcal superinfection
were analyzed, it was found that urinary catheterization
and urological intervention were significant risk factors
(Table 3).
In 43 (78.1%) of the 55 patients that developed a
superinfection, the initial therapy was changed, or a new
antibiotic (teicoplanin, fluconazole, etc.) was added to the
therapy. The duration of the treatment was significantly
longer in patients with superinfections (14 ± 6.6 days vs.
10 ± 4.2 days, P < 0.001).
4. Discussion
ESBL production has become more common among
E. coli and Klebsiella spp. isolated from urinary tract
infections worldwide. Among these isolates, resistance to
other classes of antibiotics, such as fluoroquinolones and
aminoglycosides, limits the therapeutic options in UTIs.
Carbapenems and beta-lactam/beta-lactamase inhibitor
combinations are used frequently in the treatment of UTIs

Table 2. The frequency of superinfection under treatment.
Superinfection

Ertapenem
(n = 170) (n, %)

Piperacillin-tazobactam
(n = 60) (n, %)

P

48th hour of treatment

35 (20.6)

5 (8.3)

0.05

After 48th hour of treatment

22 (12.9)

1 (1.7)

0.02

Total

50 (29.4)

5 (8.3)

0.02

Table 3. Risk factors for the enterococcal superinfection in ertapenem group at 48th hour of
treatment.
P

OR

CI

Catheterization

0.048

2.54

1.01–6.42

Diabetes mellitus

0.048

2.59

1.01–6.66

Urological intervention

0.018

2.99

1.20–7.43

The logistic regression model for the risk factors of enterococcal superinfection in ertapenem
group at 48th hour of treatment includes urinary catheterization, nephrolithiasis, diabetes
mellitus, urological intervention, urinary malignancy, recurrent urinary tract infection, and
antibiotic treatment within last 3 months. OR: Odds ratio, CI: confidence interval.
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caused by ESBL-producing enteric bacteria. Hsueh et al.
stated that ESBL production among E. coli isolates in the
Asia-Pacific region reached 33%, and nearly half of the
isolates were also resistant to quinolones (2). In this study,
carbapenems, including ertapenem, were suggested in the
empirical therapy of cUTIs because there is no resistance
to these agents. In a Spanish study, ertapenem was very
active in vitro against urinary isolates of ESBLproducing
Enterobacteriaceae (5). All of the isolates were susceptible
to ertapenem. However, the susceptibility rates to other
antimicrobials were low, for instance 15.5% to quinolones,
37.9% to cotrimoxazole, and 77.1% to piperacillintazobactam.
One of the important findings of our study was that
both ertapenem and piperacillin-tazobactam were very
effective in the treatment of cUTIs caused by ESBLpositive
E. coli and Klebsiella spp. Urine cultures obtained at the
48th hour of treatment were negative for the primary
pathogen in both treatment groups. Ertapenem, a group
1 carbapenem, seems to be a very good option in the
treatment of cUTIs because of its activity against ESBLpositive microorganisms, its elimination by the renal
route, and its pharmacokinetic properties, which allow
its use as a once-per-day treatment (6). In the literature,
the efficacy of ertapenem in UTI treatments was mostly
compared to ceftriaxone. In a prospective, randomized,
double-blind, multicenter study, Tomera et al. reported
similar microbiological success rates for the ertapenem
and ceftriaxone groups (91.8% vs. 93.0%, respectively) (7).
In a more recent randomized, double-blind, multicenter
study, the efficacies of ertapenem and ceftriaxone were
compared in acute pyelonephritis and other cUTIs. A
favorable microbiological response was observed in 87.0%
and 88.7% of the patients in the ertapenem and ceftriaxone
groups, respectively (4).
Piperacillin-tazobactam, a beta-lactam/beta-lactamase
inhibitor, is also effective in the treatment of various
infections caused by ESBL-positive microorganisms. It is
widely used in the treatment of UTIs, lower respiratory
tract infections, bloodstream infections, intraabdominal
infections, and complicated skin and soft tissue infections
(8). Sifuentes-Osornio et al. suggested that piperacillintazobactam is a reliable therapy in the treatment of
cUTIs requiring hospitalization (9). They reported seeing
favorable clinical responses with piperacillin-tazobactam
in 83.6% and 80.0% of early and late assessments,
respectively. Piperacillin-tazobactam was as effective as
imipenem-cilastatin for the treatment of acute complicated
pyelonephritis and cUTIs, with 83.0% and 79.9% clinical
success, respectively (10). There were no studies comparing

the efficacy of ertapenem and piperacillin-tazobactam in
the treatment of cUTIs due to ESBL-producing E. coli and
Klebsiella spp. until the current study. Therefore, our study
provides valuable data concerning the use of ertapenem
and piperacillin-tazobactam for these infections. When we
compared ertapenem and piperacillin-tazobactam, both
were effective in the treatment of cUTIs, and there was
no statistical difference between their activities. However,
it seems that ertapenem has some advantages because
of both its onceper-day usage and its convenience as an
outpatient parenteral antibiotic therapy (11).
According to our results, the most important finding
was the difference in frequency of superinfections
between the groups. The frequency of a superinfection
was significantly higher in the ertapenem group. We
detected a superinfection in one-third of patients in the
ertapenem group; however, this rate was only one-tenth
in the piperacillintazobactam group. The difference
between the two groups was the result of Enterococcus and
Pseudomonas spp., against which ertapenem is not active
(11). The LR model revealed that urinary catheterization
was an independent risk factor for the development of a
superinfection in the ertapenem group, and the presence
of diabetes mellitus in the piperacillin-tazobactam group.
In the ertapenem group, Enterococcus spp. was
the main pathogen isolated from superinfections and
was detected in 71.4% of positive urine cultures after
48 h. Urinary catheterization, diabetes mellitus, and
urological intervention were significant risk factors for the
development of an enterococcal superinfection. Ertapenem
has no activity against Enterococcus spp. or Pseudomonas
spp. Therefore, we recommend that ertapenem should
be cautiously used in cases where there is a suspicion of
Enterococcus and Pseudomonas, especially in patients with
urinary catheterization, diabetes mellitus, or urological
intervention. Urine cultures should be performed at the
48th hour for the detection of a superinfection.
As a result of superinfection, duration of treatment
lengthens; however, this did not cause mortality in our
study.. The duration of treatment was significantly longer
in patients who had developed a superinfection (P < 0.01).
In conclusion, both ertapenem and piperacillintazobactam were effective in the treatment of cUTIs caused
by ESBL-producing enteric gram-negative bacteria. The
frequency of superinfections in the ertapenem group was
significantly higher than in the piperacillin-tazobactam
group. In the presence of urinary catheterization, diabetes
mellitus, and urological intervention, patient should be
closely monitored for the development of a superinfection,
especially patients receiving ertapenem.
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